Skip to main content

ChondroGene Pens Molecular Dx Alliance With Two Malaysian Hospitals

NEW YORK, June 10 (GenomeWeb News) - ChondroGene has partnered with a pair of hospitals in Malaysia to develop a suite of molecular diagnostics for certain diseases based on its Sentinel Principle technology, the company said today.


As part of the alliance, Lam Wah EE Hospital and IslandHospital, located in Penang, will provide ChondroGene with blood samples from patients with cancer, cardiovascular disease, central nervous system disorders, and arthritis, the company said.


ChondroGene, based in Toronto, will use genetic data extracted from these samples to help it identify blood-based biomarkers for specific diseases in these areas. ChondroGene will also add the data to its database of gene-expression profiles, which the firm said currently contains profiles from controls and "several thousand people possessing a wide range of disease conditions."


The hospitals said they would offer ChondroGene's tests to their patients as the diagnostics become available.

K. Wayne Marshall, president and CEO of ChondroGene, said he "expect[s] to enter into similar relationships with other organizations around the world in the future in order to further expand the genetic diversity of our gene expression database. ..."

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.